Catalyst
Slingshot members are tracking this event:
European Medicines Agency Agrees to Review PharmaMar's (PHM.MC) Marketing Authorization Application (MAA) for Aplidin® (plitidepsin) in Combination with Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (MM)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| PHM.MC |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 28, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Marketing Authorization Application, Maa, Aplidin, Plitidepsin, Dexamethasone, Relapsed/refractory Multiple Myeloma, Mm
